Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.

Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 May;17(5):268-270 Authors: Kantarjian HM PMID: 31188803 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Related Links:

In children with acute lymphoblastic leukemia (ALL) at risk for central nervous system (CNS) relapse, a higher dose of chemotherapy plus two extra doses of intrathecal therapy during early induction can obviate the need for prophylactic cranial irradiation, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Abstract Adoptive immunotherapy of cancer using T cells expressing chimeric antigen receptors (CARs) is now an approved treatment for non-Hodgkin lymphoma (NHL) and B cell acute lymphoblastic leukemia (B-ALL), inducing high response rates in patients. The infusion products are generated by using retro- or lentiviral transduction to induce CAR expression in T cells followed by an in vitro expansion protocol. However, use of viral vectors is cumbersome and is associated with increased costs due to the required high titers, replication-competent retrovirus (RCR) detection and production/use in a biosafety level 2 cul...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
AbstractPresence of minimal residual disease (MRD) following induction chemotherapy is a well-recognized risk factor to predict relapse in acute lymphoblastic leukemia (ALL). There is paucity of data on MRD and outcome in ALL from India. We share our experience in establishing a flow cytometry-based MRD assay for ALL with emphasis on determination of the number of patients who had MRD on day 35 of induction therapy and its correlation with outcome and other prognostic factors. We prospectively studied MRD in patients with ALL less than 25  years who achieved morphological complete remission with induction therapy. The...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
ski A Abstract The polyether ionophore salinomycin (SAL) has captured much interest because of its potent activity against cancer cells and cancer stem cells. Our previous studies have indicated that C1/C20 double-modification of SAL is a useful strategy to generate diverse agents with promising biological activity profiles. Thus, in this paper, we describe the synthesis of a new class of SAL analogs that combine key modifications at the C1 and C20 positions. The activity of the obtained SAL derivatives was evaluated using primary acute lymphoblastic leukemia, human breast adenocarcinoma and normal mammary epithel...
Source: ChemMedChem - Category: Chemistry Authors: Tags: ChemMedChem Source Type: research
Publication date: Available online 6 November 2019Source: Seminars in Cancer BiologyAuthor(s): Stefanie Lesch, Mohamed-Reda Benmebarek, Bruno L. Cadilha, Stefan Stoiber, Marion Subklewe, Stefan Endres, Sebastian KoboldAbstractThe remarkable success of chimeric antigen receptor (CAR)-engineered T cells in pre-B cell acute lymphoblastic leukemia (ALL) and B cell lymphoma led to the approval of anti-CD19 CAR T cells as the first ever CAR T cell therapy in 2017. However, with the number of CAR T cell-treated patients increasing, observations of tumor escape and resistance to CAR T cell therapy with disease relapse are demonstr...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Thromboembolism is a serious toxicity of acute lymphoblastic leukemia treatment, and contributes to substantial morbidity and mortality. Several single nucleotide polymorphisms have been associated with thromboembolism in the general population; however, their impact in patients with acute lymphoblastic leukemia, particularly in children, remains uncertain.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Full Length Article Source Type: research
In this study, amino-oxy-diarylquinolines were designed using structure-guided molecular hybridization strategy and fusing of the pharmacophore templates of nevirapine (NVP), efavirenz (EFV), etravirine (ETV, TMC125) and rilpivirine (RPV, TMC278). The anti-HIV-1 reverse transcriptase (RT) activity was evaluated using standard ELISA method, and the cytotoxic activity was performed using MTT and XTT assays. The primary bioassay results indicated that 2-amino-4-oxy-diarylquinolines possess moderate inhibitory properties against HIV-1 RT. Molecular docking results showed that 2-amino-4-oxy-diarylquinolines 8(a-d) interacted wi...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Tags: Original Article Source Type: research
Condition:   Acute Lymphoblastic Leukemia Intervention:   Biological: CTA101 Sponsors:   Kai Lin Xu; Jun Nian Zheng;   Nanjing Bioheng Biotech Co., Ltd. Recruiting
Source: - Category: Research Source Type: clinical trials
AbstractAlthough complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody –drug conjugates and chimeric antigen receptor T cell therapy are changing the therapy landscape for B- ALL. Blinatumomab, a bi-specific T cell engager, has been approved for patients with relapsed/refractory and minimal residual disease positive B-ALL. This review summarized data from recent clin ical trials of blinatumomab for B-ALL treatment.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
We describe three clinical scenarios in which CAR T- cell immunotherapy interfered with HIV-1 testing including: (1) routine infectious disease screening prior to stem cell transplantation in a 16-year-old female with B-cell acute lymphoblastic leukemia, status post CAR T- cell treatment (2) routine infectious disease screening prior to 2nd CAR T- cell collection in a 65-year-old male with diffuse large B-cell lymphoma who failed initial CAR T- cell treatment and (3) routine infectious risk assessment following an occupational health exposure from a 58 -year-old male with multiple myeloma, status post CAR T- cell treatment...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Clin Microbiol Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Hematology | Leukemia